Emergent BioSolutions Inc. filed a Form 8-K on November 4, 2026, disclosing a contract modification exercising an option period to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War for a value of up to $22.3 million.

Key Highlights

  • Contract value: The modification is valued at up to $22.3 million for the supply of BioThrax (Anthrax Vaccine Adsorbed).
  • First delivery: The first delivery, valued at approximately $7.4 million, is set to begin in 2026, according to the filing.
  • Remaining deliveries: Deliveries beyond the initial shipment are expected in 2027, the company disclosed.
  • Existing contract vehicle: The modification falls under an indefinite-delivery/indefinite-quantity contract led by the Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense.
  • End use: BioThrax will be supplied for use by all branches of the U.S. military as pre-exposure prophylaxis for anthrax disease, per the filing.
  • Collaboration partner: The contract is managed in collaboration with the Defense Health Agency, according to the disclosure.

Emergent BioSolutions Receives BioThrax Option Exercise Under Military IDIQ Contract

According to the Form 8-K filed with the SEC on November 4, 2026, Emergent BioSolutions Inc. (NYSE:EBS) announced that it received a modification exercising an option period under an existing delivery order. The modification covers the supply of BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War and is valued at up to $22.3 million. The company disclosed that the first delivery under the modification, valued at approximately $7.4 million, will begin in 2026, with remaining deliveries expected in 2027.

The filing states that the modification is made under Emergent's existing indefinite-delivery/indefinite-quantity contract. That contract is led by the Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense, in collaboration with the Defense Health Agency. The stated purpose is to supply BioThrax for use by all branches of the U.S. military as pre-exposure prophylaxis for anthrax disease.

The company noted that the description of the modification "does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification." The company further disclosed that the full text of the modification will be filed as an exhibit to Emergent's Annual Report on Form 10-K for the fiscal year ended December 31, 2026. The Form 8-K was signed by Richard S. Lindahl, Executive Vice President and Chief Financial Officer.

What Was Disclosed

Emergent BioSolutions disclosed the receipt of a contract modification valued at up to $22.3 million to supply BioThrax to the U.S. Department of War under an existing indefinite-delivery/indefinite-quantity contract, with an initial delivery of approximately $7.4 million beginning in 2026 and remaining deliveries expected in 2027.